EP0799619A2 — Use of alpha1-adrenoreceptor antagonists in the manufacture of a medicament for the prevention and treatment of benign prostatic hyperplasia
Assigned to Baylor College of Medicine · Expires 1997-10-08 · 29y expired
What this patent protects
A method for treating or preventing a BPH in a mammal which comprises administering to said mammal an amount of a drug, comprising an α 1 -adrenoreceptor antagonist or pharmaceutically acceptable acid addition salt thereof, effective for treating or preventing the BPH.
USPTO Abstract
A method for treating or preventing a BPH in a mammal which comprises administering to said mammal an amount of a drug, comprising an α 1 -adrenoreceptor antagonist or pharmaceutically acceptable acid addition salt thereof, effective for treating or preventing the BPH.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.